Clinical Study Update on SYN321
Progress of SYN321
Synartro is making significant strides with its innovative candidate drug SYN321, aimed at treating knee osteoarthritis through intra-articular administration. This clinical study is progressing smoothly, focusing on crucial aspects such as safety, tolerability, pharmacokinetics (PK), and early efficacy signals. The study received necessary approvals from the local health regulatory authorities and began recruiting participants in the latter part of 2025. A total cohort of 35 individuals dealing with knee osteoarthritis has been enrolled since then.
Cohorts and Study Details
The study is structured into four distinct cohorts, with participants recruited and treated within a concise four-month period: Cohort 1 consists of 7 patients, Cohort 2 includes 8, Cohort 3 has 8 participants, and Cohort 4 encompasses 12 individuals. After thorough evaluations by the internal safety review committee, the promising results from Cohort 3's highest dose have led to an expansion involving Cohort 4.
Status of the Study
Cohorts 1 through 3 have successfully completed their part of the study adhering to the established protocols, while Cohort 4 continues its progress. Follow-up assessments for Participants in this cohort are scheduled for weeks 4 and 6. The last patient's visit is slated for the start of February 2026, with unblinding planned for mid-March, which will facilitate detailed analyses of the gathered safety and efficacy data.
Interim Safety Observations from the Study
The interim data accumulated thus far reinforces preclinical findings, showing no serious adverse events associated with the investigational medicinal product. The observed side effects align with those typically linked to intra-articular injections. Fortunately, there have been no reports of allergic reactions or adverse immunological responses to date.
Pharmacokinetic Findings
The clinical study has shown promising pharmacokinetic results. The average maximum concentration (Cmax) values in the plasma from the first two cohorts indicate minimal systemic exposure to diclofenac, a key component of SYN321. Data from Cohorts 3 and 4 is still pending, but preliminary findings reveal that plasma levels of diclofenac-derived by-products remain below detectable limits. These results support SYN321's intended slow-release formulation, highlighting its potential as a treatment option for knee osteoarthritis.
Contact Information
For additional insights into the clinical study or further inquiries about SYN321, you may reach out to Magnus Hurst, the CFO, and acting CEO of Synartro. Magnus Hurst can be contacted via telephone or other means available upon request.
Frequently Asked Questions
What is SYN321 used for?
SYN321 is being studied as an intra-articular treatment for knee osteoarthritis, aiming to improve patient outcomes.
How many participants are involved in the SYN321 study?
The study involves a total of 35 participants, recruited into four cohorts.
What are the results from the SYN321 study so far?
Preliminary findings indicate no serious adverse events related to the treatment, along with promising pharmacokinetic data.
How does the study ensure safety for participants?
The study has included rigorous monitoring and a review by an internal safety committee to ensure participant safety throughout the trial.
When will the results of the SYN321 study be available?
The study's unblinding is expected in mid-March 2026, when detailed analyses will begin.
